Prognostic impact of hemoglobin levels on treatment outcome in patients with nasopharyngeal carcinoma treated with sequential chemoradiotherapy or radiotherapy alone

Cancer

Volumn 101, Issue 2, 2004, Pages 307-316

  Chua, Daniel T T ^a   Sham, Jonathan S T ^a   Choy, Damon T K ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Hemoglobin; Induction chemotherapy; Nasopharyngeal carcinoma; Prognostic factor; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; EPIRUBICIN; HEMOGLOBIN;

ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; NASOPHARYNX CARCINOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RADIATION SICKNESS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TREATMENT OUTCOME;

AGED; ANEMIA; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM METASTASIS; PROGNOSIS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME;

EID: 3042737590     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20366     Document Type: Article

References (36)

1. Pedersen D, Sogaard H, Overgaard J, Bentzen SM. Prognostic value of pretreatment factors in patients with locally advanced carcinoma of the uterine cervix treated by radiotherapy alone. Acta Oncol. 1995;34:787-795.
2. Hong JH, Tsai CS, Chang JT, et al. The prognostic significance of pre- and posttreatment SCC levels in patients with squamous cell carcinoma of the cervix treated by radiotherapy. Int J Radiat Oncol Biol Phys. 1998;41:823-830.
3. Kagei K, Shirato H, Nishioka T, et al. High-dose-rate intracavitary irradiation using linear source arrangement for Stage II and III squamous cell carcinoma of the uterine cervix. Radiother Oncol. 1998;47:207-213.
4. Takeshi K, Katsuyuki K, Yoshiaki T, et al. Definitive radiotherapy combined with high-dose-rate brachytherapy for Stage III carcinoma of the uterine cervix: retrospective analysis of prognostic factors concerning patient characteristics and treatment parameters. Int J Radiat Oncol Biol Phys. 1998;41:319-327.
5. Kapp KS, Stuecklschweiger GF, Kapp DS, et al. Prognostic factors in patients with carcinoma of the uterine cervix treated with external beam irradiation and IR-192 high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 1998;42:531-540.
6. Fein DA, Lee WR, Hanlon AL, et al. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol. 1995;13:2077-2083.
7. Dubray B, Mosseri V, Brunin F, et al. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study. Radiology. 1996;201:553-558.
8. Warde P, O'Sullivan B, Bristow RG, et al. T1/T2 glottic cancer managed by external beam radiotherapy: the influence of pretreatment hemoglobin on local control. Int J Radiat Oncol Biol Phys. 1998;41:347-353.
9. Lee WR, Berkey B, Marcial V, et al. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys. 1998;42:1069-1075.
10. Grant DG, Hussain A, Hurman D. Pre-treatment anemia alters outcome in early squamous cell carcinoma of the larynx treated by radical radiotherapy. J Laryngol Otol. 1999;113:829-833.
11. Skladowski K, Tarnawski R, Maciejewski B, Wygoda A, Slosarek K. Clinical radiobiology of glottic T1 squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 1999;43:101-106.
12. Schafer U, Micke O, Muller SB, Schuller P, Willich N. Hemoglobin as an independent prognostic factor in the radiotherapy of head and neck tumors. Strahlenther Onkol. 2003;179:527-534.
13. Bachouchi M, Cvitkovic E, Azli N, et al. High complete response in advanced nasopharyngeal carcinoma with bleomycin, epirubicin, and cisplatin before radiotherapy. J Natl Cancer Inst. 1990;82:616-620.
14. Dimery IW, Peters LJ, Goepfert H, et al. Effectiveness of combined induction chemotherapy and radiotherapy in advanced nasopharyngeal carcinoma. J Clin Oncol. 1993;11:1919-1928.
15. Garden AS, Lippman SM, Morrison WH, et al. Does induction chemotherapy have a role in the management of nasopharyngeal carcinoma? Results of treatment in the era of computerized tomography. Int J Radiat Oncol Biol Phys. 1996;36:1005-1012.
16. Hong RL, Ting LL, Ko JY, et al. Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol. 2001;19:4305-4313.
17. International Nasopharynx Cancer Study Group. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in Stage IV (≥ N2, MO) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. VUMCA I trial. Int J Radiat Oncol Biol Phys. 1996;35:463-469.
18. Chua DT, Sham JS, Choy D, et al. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Cancer. 1998;83:2270-2283.
19. Ma J, Mai HQ, Hong MH, et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol. 2001;19:1350-1357.
20. Hareyama M, Sakata K, Shirato H, et al. A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma. Cancer. 2002;94:2217-2223.
21. Fleming ID, Cooper JS, Hensen DE, et al., editors. AJCC cancer staging manual (5th edition). Philadelphia: Lippincott-Raven, 1998.
22. Altun M, Demiral AN, Meral R, et al. Prognostic significance of hemoglobin concentration in nasopharyngeal carcinoma: does treatment-induced anemia have negative effect? In Vivo. 2003;17:483-487.
23. van Acht MJ, Hermans J, Boks DE, Leer JW. The prognostic value of hemoglobin and a decrease in hemoglobin during radiotherapy in laryngeal carcinoma. Radiother Oncol. 1992;23:229-235.
24. Tarnawski R, Skladowski K, Maciejewski B. Prognostic value of hemoglobin concentration in radiotherapy for cancer of supraglottic larynx. Int J Radiat Oncol Biol Phys. 1997;38:1007-1011.
25. Wagner W, Hermann R, Hartlapp J, et al. Prognostic value of hemoglobin concentrations in patients with advanced head and neck cancer treated with combined radio-chemotherapy and surgery. Strahlenther Onkol. 2000;176:73-80.
26. Stadler P, Becker A, Feldmann HJ, et al. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys. 1999;44:749-754.
27. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 2004;22:69-76.
28. Becker A, Stadler P, Lavey RS, et al. Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys. 2000;46:459-466.
29. Seidenfeld J, Piper M, Flamm C, et al. Epoetin treatment of anemia associated with cancer therapy: a systemic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst. 2001;93:1204-1214.
30. Lavey RS, Dempsey WH. Erythropoietin increases hemoglobin in cancer patients during radiation therapy. Int J Radiat Oncol Biol Phys. 1993;27:1147-1152.
31. Dusenbery KE, McGuire WA, Holt PJ, Baker PB, Loure CR, Bruce NC. Erythropoietin increases hemoglobin during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys. 1994;29:1079-1084.
32. Sweeney PJ, Nicolae D, Ignacio L, et al. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, Phase II trial. Br J Cancer. 1998;77:1996-2002.
33. Henke M, Guttenberger R, Barke A, Pajonk F, Potter R, Frommhold H. Erythropoietin for patients undergoing radiotherapy: a pilot study. Radiother Oncol. 1999;50:185-190.
34. Glaser CM, Millesi W, Kornek GV, et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys. 2001;50:705-715.
35. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255-1260.
36. Rischin D, Corry J, Smith J, Stewart J, Hughes P, Peters L. Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation. J Clin Oncol. 2002;20:1845-1852.